The landscape of drug sensitivity and resistance in sarcoma
Ahmad Al Shihabi, Peyton Tebon, Huyen Thi Lam Nguyen, Jomjit Chantharasamee, Sara Sartini, Ardalan Davarifar, Alexandra Y Jensen, Miranda Diaz-Infante, Hannah C. Cox, Alfredo Enrique Gonzalez, Summer Norris, Jantzen Sperry, Jonathan Nakashima, Nasrin Tavanaie, Helena Winata, Sorel Fitz‐Gibbon, Takafumi N. Yamaguchi, Jae Hoon Jeong, Sarah Dry, Arun S. Singh, Bartosz Chmielowski, Joseph G. Crompton, Anusha Kalbasi, Fritz C. Eilber, Francis J. Hornicek, Nicholas M. Bernthal, Scott D. Nelson, Paul C. Boutros, Noah Federman, Jane Yanagawa, Alice Soragni
Abstract
Sarcomas are rare malignancies with over 100 distinct histological subtypes. Their rarity and heterogeneity pose significant challenges to identifying effective therapies, and approved regimens show varied responses. Novel, personalized approaches to therapy are needed to improve patient outcomes. Patient-derived tumor organoids (PDTOs) model tumor behavior across an array of malignancies. We leverage PDTOs to characterize the landscape of drug resistance and sensitivity in sarcoma, collecting 194 specimens from 126 patients spanning 24 distinct sarcoma subtypes. Our high-throughput organoid screening pipeline tested single agents and combinations, with results available within a week from surgery. Drug sensitivity correlated with clinical features such as tumor subtype, treatment history, and disease trajectory. PDTO screening can facilitate optimal drug selection and mirror patient outcomes in sarcoma. We could identify at least one FDA-approved or NCCN-recommended effective regimen for 59% of the specimens, demonstrating the potential of our pipeline to provide actionable treatment information.